Home › Weight Loss › Wegovy UK

Wegovy UK: Injection and Weight Loss Pill Guide

Wegovy UK is available in two forms: the once-weekly semaglutide injection, licensed here since 2023, and the once-daily Wegovy pill, which the MHRA approved on 11 June 20267 as the first oral GLP-1 medicine licensed in the UK for weight management. Both contain the same active ingredient, semaglutide, and both are prescription-only medicines available privately following a clinical assessment, or on the NHS through specialist services for a much narrower group of patients. This guide covers eligibility, how the injection and the tablet differ, dosing for both, what they cost, side effects, and how to obtain either safely from a regulated UK pharmacy.

✍️ Written by Shadeia Younis, Superintendent Pharmacist (GPhC No. 2052119) and the Slinic Clinical Team
Last medically reviewed: 26 July 2026 · Last updated: 26 July 2026 · Prices last verified: 26 July 2026

Wegovy UK at a glance

What is Wegovy?

Wegovy is a brand name. The medicine inside it is semaglutide, made by Novo Nordisk. Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a hormone your gut releases after eating that signals fullness to the brain.

In the UK, Wegovy is licensed for weight management in adults as an adjunct to a reduced-calorie diet and increased physical activity. That word adjunct is not filler. The medicine is not licensed as a standalone intervention, and the trial results everyone quotes were achieved alongside structured dietary and lifestyle support, not instead of it.

Wegovy, Ozempic and Rybelsus: three products, one molecule

This is the single most common source of confusion in UK weight management, and it matters because the products are not interchangeable.

The medicine versus the service

Semaglutide is the same molecule regardless of which UK pharmacy supplies it, provided it is genuine licensed stock from the authorised supply chain. What varies enormously between providers is everything around it: the depth of the clinical assessment, who reviews your case, whether anyone follows up, how side effects are managed, and what happens when progress stalls or you want to stop. Comparing providers on price alone compares the identical component and ignores the variable one.

Wegovy injection versus Wegovy pill

Both deliver semaglutide. The practical differences are substantial, and neither is universally better.

Who each may suit

The injection may suit you better if you would rather think about treatment once a week than every morning, you are comfortable with needles or willing to become so, your mornings are unpredictable, or you already take oral medicines whose timing would be complicated by the fasting window.

The tablet may suit you better if you have a genuine needle phobia, you travel frequently and find cold-chain logistics a problem, you already have a settled morning routine that a fasting window fits into, or you have found injection-site reactions troublesome.

Is the Wegovy pill available in the UK?

Yes, but with an important distinction between approval and supply that a lot of coverage has blurred.

The MHRA approved oral semaglutide on 11 June 20267 for weight management in adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related comorbidity. It is the first oral GLP-1 receptor agonist licensed for weight management in the UK, and the UK was the third jurisdiction to approve it, after the United States and the United Arab Emirates.

Supply is being introduced in phases. Novo Nordisk has described a phased UK rollout intended to keep supply consistent. The lower titration strengths entered circulation first, with the higher strengths following progressively. In practice this means a new patient starting at the bottom of the titration ladder is generally unaffected, but availability of a specific strength at a specific moment can vary.

How Wegovy works

Semaglutide is a GLP-1 receptor agonist. It mimics and amplifies a hormone your body already produces after eating, and it works on several fronts at once.

What it is not

Semaglutide is not a stimulant, does not raise your metabolic rate, and does not block absorption of what you eat. Weight loss happens because appetite falls and energy intake follows. If intake does not fall — because portion sizes stay the same out of habit, or because reduced appetite is offset by high-calorie liquids — results will be limited whatever the dose.

Why the two forms feel different

The weekly injection produces relatively steady drug levels across the week. The daily tablet produces a daily peak and trough. Some people notice appetite effects more variably through the day on the tablet, particularly early in treatment. Both reach comparable exposure at maintenance doses when taken correctly, which is why the fasting rules for the tablet matter so much.

How much weight can people lose on Wegovy?

The evidence base for semaglutide is large and genuinely strong. It is also routinely misquoted, so it is worth separating what the trials found from what an individual should expect.

What the averages do not tell you

• An average contains a wide spread. Some participants lost far more, some far less. A mean figure presented as an expected personal result is misleading.
• Trial conditions are not everyday conditions. Participants received structured dietary support, regular contact and monitoring at an intensity most people do not have.
• Results depend on more than the medicine. Starting weight, dose reached, consistency, diet, activity, sleep, other conditions and other medicines all influence the outcome.
• Duration matters. These are figures at 64 to 68 weeks. Results at 12 weeks look very different.

Semaglutide, Wegovy and type 2 diabetes

Semaglutide is licensed in the UK for two entirely separate purposes under different brand names, and the distinction has practical consequences if you have diabetes.

• Different products. Wegovy and the Wegovy pill are licensed for weight management. Ozempic and Rybelsus contain the same molecule but are licensed for type 2 diabetes. They are not substitutes for one another, and the strengths differ.
• Different prescribing route. Semaglutide for type 2 diabetes is prescribed through diabetes care, usually your GP practice or a diabetes specialist. That route is not subject to the specialist weight management service bottleneck that limits NHS Wegovy.
• Different clinical priorities. When prescribed for diabetes the focus is HbA1c, glycaemic control and cardiovascular risk, with weight reduction as a welcome secondary benefit. When prescribed for weight management the priorities reverse.

Private weight-management prescribing for someone with type 2 diabetes is common and entirely legitimate — BMI 27 or above with type 2 diabetes meets the licensed criteria. It requires your HbA1c, current medicines and diabetes history to form part of the assessment, and coordination with your GP on any dose adjustments.

Why some people lose weight faster than others

Two people on the same dose of the same medicine, starting at similar weights, can end up with markedly different results. This is the question patients ask most often once treatment is under way, and it deserves a proper answer rather than a shrug.

Who may qualify for Wegovy privately in the UK?

Private eligibility follows the terms of the UK licence, then narrows according to each provider’s clinical governance. The licensed criteria are the same for the injection and the tablet.

Weight-related conditions that may qualify at BMI 27 to under 30

• Type 2 diabetes
• Prediabetes
• High blood pressure
• Dyslipidaemia, including raised cholesterol
• Obstructive sleep apnoea
• Cardiovascular disease

Lower thresholds for some ethnic backgrounds

For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, a lower BMI threshold is commonly applied — usually reduced by around 2.5 kg/m² — because cardiometabolic risk occurs at lower BMI in these populations. NICE applies this adjustment in its NHS criteria12. Whether and how a private provider applies it is a matter of their clinical policy.

What else is assessed

• Full medical history, including anything you might assume is irrelevant.
• Every medicine you take — prescription, over-the-counter, herbal and supplements. This matters more for the tablet than most people realise, because the fasting window interacts with the timing of other oral medicines.
• Pregnancy status and plans. Semaglutide is not recommended in pregnancy and needs establishing before treatment, not after.
• Identity and weight verification. A legitimate provider verifies who you are and confirms your weight rather than accepting a self-reported figure unchecked10.
• Any current GLP-1 treatment. Two GLP-1 medicines must never be taken together, and that includes the Wegovy injection and the Wegovy pill.
• Eating disorder history, current or past.

Wegovy and specific weight-related conditions

Several conditions are both a reason you might qualify at a lower BMI and a reason treatment needs particular care.

Who may not be suitable for Wegovy?

Three categories are often presented as one undifferentiated list. They are not equivalent, and the distinction is useful. The authoritative source is the current UK Summary of Product Characteristics and the patient information leaflet supplied with your medicine6.

Licensed contraindication

Wegovy must not be used if you have known serious hypersensitivity to semaglutide or to any of the excipients in the product.

Warnings and precautions in the product information

Provider-specific clinical exclusions

Beyond the licence, providers apply their own criteria reflecting their clinical governance and the limits of a remote service — commonly current or past eating disorders, certain mental health presentations, complex polypharmacy, or situations better managed face to face. These are legitimate clinical decisions but they are policy rather than universal medical fact, which is why one clinic may decline where another accepts.

Wegovy injection doses

The maintenance dose of 2.4 mg once weekly is reached by starting low and escalating in steps, to reduce the likelihood of gastrointestinal symptoms.

How escalation works in practice

• Four weeks at each step is the standard interval. It is the point at which a dose increase may be considered, not a schedule everyone must follow. Staying longer at a dose is a legitimate clinical decision and often the right one.
• Escalation is not automatic. It should follow a review of how you are responding and how well you are tolerating the current dose. Increasing while significant symptoms persist usually worsens those symptoms without improving results.
• Steps should not be skipped. Jumping strengths without prescriber authorisation substantially increases the risk of adverse effects.
• 2.4 mg is not compulsory. If appetite is well controlled and weight is coming down at a lower dose, there may be no clinical reason to increase.

Why treatment sometimes does not work

Most people respond well. A minority do not, and the reasons are usually identifiable rather than mysterious. In rough order of how often they turn out to be the explanation:

When increasing the dose is not the right answer

There is a strong assumption among patients that a stalled result means the dose should go up. Sometimes it should. Often it should not, and escalating into the wrong situation makes things worse rather than better.

Reasons a prescriber may hold the dose

• You are still having significant side effects. Increasing while nausea, vomiting or diarrhoea are unresolved reliably worsens them, and the most common consequence is that the patient abandons treatment altogether.
• You are still losing weight steadily. If the current dose is working, there is no clinical argument for adding side-effect risk and cost to achieve something already happening.
• The plateau is short. Two or three weeks without movement is normal variation, not a plateau, and reacting to it with a dose increase treats noise as signal.
• Something other than the dose explains it. Liquid calories, a new medicine, poor sleep, a period of low adherence, or tablet technique.
• Intake has dropped too far already. If you are struggling to eat adequately, more appetite suppression is the opposite of what is needed.
• A symptom needs investigating first. New abdominal pain, in particular, is a reason to pause and assess rather than escalate.

Wegovy 7.2 mg: the higher-dose option

A 7.2 mg once-weekly strength is licensed in the UK8, roughly three times the standard 2.4 mg maintenance dose. It is the highest licensed semaglutide dose available, and it is frequently misunderstood, so it is worth being precise about what it is and who it is for.

It is not a starting dose

This is the single most important point. Nobody begins treatment on 7.2 mg. The standard titration still applies in full — 0.25 mg, then 0.5, 1, 1.7 and 2.4 mg, with the usual minimum interval at each step. Only after you are established on 2.4 mg does 7.2 mg become a question your prescriber might consider, and typically only after you have been on 2.4 mg for a period and the clinical picture supports going further.

Who it may be considered for

Broadly, someone who has completed the full titration, is tolerating 2.4 mg well, and whose weight loss has slowed or fallen short of what their clinical situation calls for. It is a response-driven decision, not an upgrade to request. It is generally not appropriate if you had significant side effects at lower doses, if you have not completed the standard escalation, or if there is something in your medical history that makes a higher exposure unwise.

What the evidence shows

The 7.2 mg dose was studied in STEP UP3, a phase 3b trial of around 1,400 adults with obesity and without type 2 diabetes, over 72 weeks, comparing 7.2 mg against 2.4 mg and placebo alongside lifestyle support.

Side effects at the higher dose

The overall safety profile in STEP UP was broadly consistent with 2.4 mg, and gastrointestinal effects followed the familiar pattern — most common during escalation, easing over time.

One finding is specific enough to be worth knowing about in advance. Dysaesthesia — an altered or tingling sensation in the skin — was reported by close to a quarter of participants on 7.2 mg, considerably more than at 2.4 mg. In the large majority of cases it resolved while treatment continued. It is not dangerous, but it is unsettling if nobody has mentioned it to you, and it is the kind of thing that leads people to stop treatment unnecessarily. Report it to your prescriber if it happens rather than assuming something has gone wrong.

Is it better than Mounjaro? A reasonable question, and not one with a clean answer. The 7.2 mg strength narrows the gap in average weight reduction between semaglutide and tirzepatide, but the two have never been compared head to head at those doses in a single trial. Cross-trial comparison is not valid evidence. See our Mounjaro UK guide and our Mounjaro versus Wegovy comparison.

What is the best Wegovy dose?

There is no universally best dose. The aim is the lowest dose that produces a good result and that you tolerate well.

Higher doses produce greater average weight reduction across populations — that is a real finding. But averages describe groups, not individuals, and several reasons argue against automatically escalating to the top of the ladder: some people respond strongly at lower doses; side effects generally increase with dose; escalating quickly raises the likelihood of gastrointestinal side effects without reliably improving the final outcome; and cost usually scales with dose. The decision belongs with your prescriber, based on your response, tolerance, progress and medical history.

Wegovy tablet doses and how to take them

The tablet has its own titration ladder, and the numbers look nothing like the injection’s because oral absorption differs so much. The two connect at the top: 2.4 mg weekly by injection corresponds to 25 mg daily by tablet, and the licence allows a direct switch between them.

How to take the tablet correctly

Missing a tablet

A missed daily tablet is skipped entirely. Do not take two tablets to catch up, and do not take a missed tablet later in the day once you have eaten, because the fasting condition has gone. Resume your normal single daily dose the following morning. If you miss several consecutive days, contact your prescriber before resuming, as a lower restart dose may be appropriate.

What happens at your first consultation

Knowing what to expect makes the assessment easier to complete properly, and completing it properly is what makes it safe.

What you will be asked

• Your height and current weight, and how your weight has changed over time
• Previous weight-loss attempts, including any medication
• Your full medical history, including anything you might assume is irrelevant
• Every medicine you take — prescription, over-the-counter, herbal and supplements, with the times of day you take them
• Whether you are pregnant, breastfeeding or planning a pregnancy
• Any history of eating disorders
• Whether you have surgery or a procedure planned
• Your alcohol intake
• Your morning routine, if you are considering the tablet — the fasting window has to fit your actual life

What to have ready

• An accurate current weight — weigh yourself rather than estimating
• A list of your medicines with doses and timings
• Photo ID
• If transferring from another provider: your current medicine, dose, how long you have been on it, and evidence such as a dispensing label or order history

How to use the Wegovy pen

This is an overview. The Instructions for Use supplied with your pen are the authoritative source and should be read fully before your first injection.

• Once weekly, same day each week. Any time of day, with or without food.
• Check the pen before use. The liquid should be clear and colourless. Do not use it if it is cloudy, discoloured, contains particles, has been frozen, or looks damaged.
• Use a new needle every time. Reusing needles blunts the tip, increases pain and injection-site reactions, and risks blockage.
• Inject into an approved site and hold the pen in place for the full count specified, so the complete dose is delivered.
• Remove the needle immediately afterwards and dispose of it in a sharps bin. Never store the pen with a needle attached.
• Never share your pen, even with a new needle.
• If the pen appears faulty, do not work around it. Contact your pharmacy.

Where to inject

Wegovy is injected subcutaneously — into the fat layer just under the skin, not into muscle or a vein. Approved sites are the abdomen (avoiding the area immediately around the navel), the front of the thigh, and the upper arm.

Rotate sites with each injection. Repeated use of the same spot can cause lumps, hardening or changes in the fat layer, which can affect absorption. Avoid skin that is bruised, tender, red, hardened, scarred or affected by a skin condition. If you also inject insulin, use a different site for each medicine.

How much does Wegovy cost in the UK?

Private Wegovy costs in the UK vary widely between providers, and the advertised figure is frequently not what you end up paying over a year.

Slinic Wegovy injection prices

Slinic Wegovy pill prices

Fixed 2026 prices with no subscription and no minimum term. The price does not change mid-treatment, and there is no discount code that expires after month one. Included: clinical assessment, prescriber review, monthly clinical reviews, needles and swabs with injectable treatment, and access to a pharmacist during treatment. All prices are subject to clinical approval before dispatch. For a full breakdown and comparison against other UK providers, see our provider price comparison.

Can you get Wegovy on the NHS?

The injection, yes — but through a much narrower route than most people expect. The tablet, not currently at all.

NHS criteria for the Wegovy injection

• Initiated within a specialist weight management service — commonly described as Tier 3 — not by your GP directly
• BMI thresholds set by TA875, with the usual 2.5 kg/m² downward adjustment for certain ethnic backgrounds
• At least one weight-related comorbidity
• Funded for a maximum of two years
• Continuation typically requires a demonstrated response at review

Your GP can refer you to a specialist service but cannot generally initiate treatment themselves under this route. Waiting times for specialist weight management services vary from weeks to well over a year depending on area.

The four UK nations

NICE appraisals apply to England and, through separate arrangements, generally to Wales and Northern Ireland. Scotland has its own process through the Scottish Medicines Consortium. Local implementation, service availability and waiting times differ across all four nations, so if you are outside England, check your own nation’s current position rather than assuming the arrangements described here apply.

Your first weeks on Wegovy

The opening month is when most people either settle into treatment or decide it is not for them. Knowing what is normal helps you tell the difference between an adjustment period and a genuine problem.

On the injection

On the tablet

The first month looks different, because the routine is the harder part rather than the dose. Most people find the fasting window is the thing that takes adjusting to, not the medicine. It is worth setting an alarm, keeping a glass of water by the bed, and deciding in advance what time you will actually be able to eat breakfast, because working that out on day one tends to produce a week of missed or badly-taken doses.

If by the end of the first month you have repeatedly taken the tablet with food, taken it late, or skipped it because the routine did not fit, that is worth raising at review rather than pushing on. Switching to the weekly injection is a reasonable answer and not a failure.

Wegovy side effects

Most side effects are gastrointestinal, most appear during titration or shortly after a dose increase, and most settle as the body adjusts. In the clinical trials nausea was the most frequently reported effect, followed by diarrhoea and vomiting, and these were typically mild to moderate. The current patient information leaflet and the BNF entry15 are the authoritative sources for the full profile.

Reducing side effects

• Eat smaller portions. Because gastric emptying is slower, a normal-sized meal can feel like a large one. The single most effective adjustment for most people.
• Eat slowly and stop when full. Fullness signals arrive earlier than you are used to.
• Avoid very fatty and fried food, particularly in the days after a dose increase.
• Keep fluids up. Reduced appetite usually reduces drinking too, and mild dehydration worsens nausea, fatigue and constipation.
• Do not increase your dose while significant symptoms persist. Discuss staying longer at the current step.
• Ask a pharmacist before adding any remedy. Delayed gastric emptying affects how oral medicines are absorbed — and if you are on the tablet, anything taken in the morning interacts with the fasting window.
• Watch for dehydration — dark urine, passing much less urine than usual, dizziness on standing, persistent thirst.

Suspected side effects can be reported through the MHRA Yellow Card scheme11, either by you or by your prescriber. Reporting helps build the safety picture for medicines that are still relatively new in widespread use.

Wegovy and other medicines

This is not an exhaustive list. Tell your prescriber about every prescription medicine, over-the-counter product, herbal remedy and supplement you take.

Wegovy, contraception and pregnancy

• Wegovy is not recommended during pregnancy.
• If you are planning to become pregnant, treatment should be stopped well in advance of conception. Semaglutide has a long half-life of roughly a week, so the interval is longer than people generally expect. Confirm the specific period with your prescriber and the current patient information leaflet.
• If you become pregnant while taking Wegovy, stop the medicine and contact your prescriber or GP straight away.
• If you are breastfeeding or planning to, discuss this with your prescriber before starting.

What should you eat while taking Wegovy?

Appetite reduction creates an opportunity and a risk at the same time. The opportunity is that eating less becomes far easier. The risk is that eating less of everything — including protein and micronutrients — produces poor nutrition, muscle loss and fatigue.

• Prioritise protein. When total intake falls, protein is the thing most worth protecting, because it helps preserve lean muscle during weight loss.
• Include fibre from vegetables, fruit, pulses and wholegrains, adjusted to your symptoms.
• Keep some healthy fats — olive oil, nuts, oily fish — while noting that very fatty meals commonly worsen nausea early on.
• Eat smaller portions more often rather than three large meals.
• Drink enough. Reduced appetite usually reduces fluid intake without you noticing, and dehydration is the mechanism behind several of the more serious problems.
• Do not crash diet. Combining very low calorie intake with semaglutide raises the risk of nutritional deficiency, muscle loss, fatigue, hair thinning and gallstones.

Can you drink alcohol on Wegovy?

There is no absolute prohibition, but several reasons for caution: it can worsen nausea and reflux, particularly in the days after a dose increase; it contributes calories that do not trigger fullness; it can affect blood glucose, which matters more if you take insulin or a sulfonylurea; it contributes to dehydration; and heavy drinking carries risks to the pancreas and liver worth considering with a medicine that has pancreatitis among its recognised risks.

Many people report wanting it less. A reduction in alcohol interest is commonly described by people on GLP-1 medicines, and is worth noting rather than fighting. Many people drink moderately without difficulty — discuss your own situation with your prescriber.

Wegovy, fasting and Ramadan

Fasting while taking semaglutide raises practical and safety questions, and the two forms are affected very differently.

On the injection

• Hydration is the main concern. Semaglutide can cause gastrointestinal fluid loss, and a long daily fast on top of that increases dehydration risk.
• Injection timing is flexible. The dose can be given at any time of day, so schedule it for whatever suits.
• Appetite reduction can make it hard to eat enough in a short eating window. Prioritising protein and fluid becomes more important, not less.
• If you take insulin or a sulfonylurea, get individual advice before fasting. That combination carries a real hypoglycaemia risk needing planning with your diabetes team.

On the tablet

The tablet needs more thought, because it already requires a fasted state and a waiting period before eating or drinking. During Ramadan that has to be worked around the pre-dawn meal and the evening break, and the arrangement will not be obvious. Plan it with your prescriber or pharmacist in advance rather than improvising during the first week, and be aware that switching temporarily to the injection is a legitimate option to discuss.

How should Wegovy be stored?

Storage differs completely between the two forms, and this is one of the practical advantages of the tablet.

The injection

• Before first use: store in a refrigerator between 2°C and 8°C. Do not freeze.
• After first use: the pen may be kept for a defined in-use period at room temperature or returned to the fridge — check the exact period and temperature range in the patient information leaflet supplied with your pen.
• Never use a pen that has been frozen, even if it has thawed and looks normal.
• Keep it in the original carton to protect it from light.
• Never store the pen with a needle attached — this can cause leaking, block the needle and allow air into the cartridge.
• Do not use it if the liquid is cloudy, discoloured or contains particles.

The tablet

Store at room temperature in the original blister and packaging. No refrigeration required, and no cold chain needed for delivery or travel. Keep it dry — do not decant tablets into a pill organiser unless your pharmacist confirms that is appropriate, because the packaging protects the formulation.

Travelling with Wegovy

What to do if you miss a dose of Wegovy

The advice is completely different for the two forms, and applying the injection rule to the tablet, or the reverse, causes real problems.

Missed injection

The five-day window exists because semaglutide has a half-life of roughly seven days. Within that window, taking the missed dose keeps drug levels in the right range. Beyond it, you risk two near-full doses overlapping. Never take two injections to make up for a missed one.

Missed tablet

Skip it entirely and take your next tablet at the normal time the following morning. Do not take two tablets to catch up, and do not take a missed tablet later the same day — once you have eaten or drunk anything other than that sip of water, the fasting condition needed for absorption has gone. If you miss several consecutive days, contact your prescriber before resuming rather than restarting at your previous dose.

Practical problems and what to do

Monitoring, blood tests and clinical reviews

Treatment does not end at the first prescription, and what happens afterwards varies far more between providers than the medicine itself does.

What ongoing review should cover

• Weight change and over what period
• Whether side effects are settling, persisting or worsening
• Whether the current dose is right, or whether staying longer is better than escalating
• Any new symptoms, particularly abdominal pain
• Any new medicines — and for tablet patients, whether the morning routine is still working
• Whether your other conditions or medicines need reviewing as weight changes, particularly blood pressure and diabetes medicines
• Eating pattern, protein intake and activity

Do you need blood tests?

Routine blood monitoring is not universally required for weight-management semaglutide in the way it is for some medicines. Your prescriber may request baseline or interval tests depending on your circumstances — for example if you have diabetes, kidney or liver concerns, or if a symptom needs investigating. Testing is a clinical judgement based on your history, not a fixed schedule. Be cautious of a provider offering no clinical review at all, and equally of one marketing extensive testing you have not been given a clinical reason for.

Do not wait for your next review to report severe abdominal pain, persistent vomiting, signs of dehydration, reduced urine output, symptoms of an allergic reaction, or sudden visual changes. Those need attention when they happen.

Wegovy versus Mounjaro

The most common comparison in UK weight management, and the one most often reduced to a single percentage.

Switching to or from Wegovy

Patients move between treatments and between providers regularly. None of it should be improvised.

Switching provider

• You will need evidence of your current treatment — a dispensing label, prescription record, letter from your previous provider, or order history showing dose and dates. Without it, a prescriber cannot safely continue you at a higher dose.
• The clinician will review continuity and tolerability — how long you have been treated, at what doses, how you tolerated them, and whether there has been a gap.
• A prolonged gap may mean restarting lower. This is a safety decision, not an administrative one.
• No supply is guaranteed until the assessment is complete.

Between the two forms, and between medicines

The licence allows people established on the 2.4 mg weekly injection to transition directly to the 25 mg daily tablet on their prescriber’s advice. If you are on a lower injection dose, the appropriate tablet starting point is a clinical judgement rather than a fixed conversion. Moving from tablet to injection is also possible and also a clinical judgement. Switching between semaglutide and tirzepatide happens frequently, usually because of response, tolerability, cost or supply — there is no official published dose-equivalence between them for weight management.

How clinicians decide whether to continue treatment

Continuation is a decision at every review, not a default. A prescriber is weighing several things: whether it is working, whether it is tolerated, whether anything has changed medically, whether it is still the right tool, and what you actually want from it. Clinical guidance for weight-management medicines generally looks for a meaningful response within a defined period at an adequate dose — NICE uses a 5% threshold at six months for NHS semaglutide. Private prescribing is not bound by that figure, but the principle is sound.

What happens when you stop Wegovy?

• Appetite generally returns. The effect on appetite signalling stops when the medicine does.
• Weight regain is common. STEP 42 demonstrated this directly: participants switched to placebo regained a substantial proportion of what they had lost, while those who continued kept losing.
• This is not a personal failure. Obesity is a chronic condition, and treatments for chronic conditions generally stop working when stopped. The same is true of blood pressure medicine.
• Habits built during treatment matter enormously. People who used the treatment period to establish sustainable eating patterns, regular activity and resistance training tend to retain more of their result.
• Stopping should be planned, not impulsive. If cost, side effects or lack of progress are prompting the thought, say so at review.

Is Wegovy a lifelong treatment?

There is no single answer, and anyone giving you one is oversimplifying. Obesity is recognised as a chronic, relapsing condition, and for some people long-term pharmacological support is appropriate in the same way it would be for hypertension. For others a defined treatment period followed by maintenance through diet, activity and behavioural change works well. Stopping treatment is not failure, and needing to continue is not failure either.

Frequently asked questions

Related guides

References

Numbered citations in the text link to the sources below. Trial figures quoted on this page are taken from the primary publications listed here rather than from secondary reporting.

Clinical trials

1. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
2. Rubino D, Abrahamsson N, Davies M, et al; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
3. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 2025.
4. Wharton S, Lingvay I, Bogdanski P, et al; OASIS 4 Study Group. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077–1087. doi:10.1056/NEJMoa2500969
5. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394

Regulatory and licensing

6. electronic Medicines Compendium — Wegovy Summary of Product Characteristics and Patient Information Leaflets for all presentations, including the 7.2 mg pen and the oral tablet.
7. MHRA — approval of oral semaglutide (Wegovy tablets) for weight management, statement published 11 June 2026. Reported in The Pharmaceutical Journal.
8. MHRA — single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity. GOV.UK, 14 April 2026.
9. MHRA — marketing authorisations and product information portal, including safety communications on GLP-1 receptor agonists.
10. General Pharmaceutical Council — registers of pharmacies and pharmacy professionals.
11. MHRA Yellow Card scheme — reporting suspected adverse drug reactions.

UK guidance

12. NICE TA875 — Semaglutide for managing overweight and obesity, March 2023.
13. NICE — technology appraisal of oral semaglutide for weight management, in development. Check the current status before relying on the NHS funding position stated on this page.
14. NHS England — weight management injections: access, eligibility and service arrangements.
15. British National Formulary — semaglutide.
16. Centre for Perioperative Care — guidance on GLP-1 receptor agonists and anaesthesia.
17. Faculty of Sexual and Reproductive Healthcare — contraception guidance.

All sources accessed August 2026. Where guidance conflicts, the current UK Summary of Product Characteristics takes precedence. Regulatory positions, supply and NHS commissioning arrangements in this area change frequently, so this page is reviewed on a scheduled basis and the review date shown at the top reflects the last check.

Written and clinically reviewed by Shadeia Younis, Superintendent Pharmacist (GPhC No. 2052119). This page is general information and does not replace advice from a qualified healthcare professional. Wegovy (semaglutide) is a prescription-only medicine in both injection and tablet form, is supplied only after an individual clinical assessment by a UK-registered prescriber, and is not suitable for everyone. It is licensed for use alongside a reduced-calorie diet and increased physical activity. Individual results vary. Treatment is dispensed from GPhC-registered premises No. 1033729.